Co-led by UNC School of Medicine’s John Buse, MD, PhD, researchers discover how treatment of hypercortisolism could improve glucose control and promote weight loss in diabetes.

Study reveals hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes. John Buse, MD, PhD, director of UNC’s Diabetes Care Center, is lead author.

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and/or chronic kidney disease.

Researchers at the UNC School of Medicine have proven that antibiotic-resistant strains of a harmful bacteria thrive in a diabetic infection environment.

Randomized, placebo-controlled trial finds that low-dose semaglutide reduces amount of alcohol consumption, alcohol cravings, and heavy drinking days. Reductions in cigarettes per day were also seen.

Nina Jain, MD, MBA, professor of pediatric endocrinology, and Ali Calikoglu, MD, retired professor of pediatrics, both at the UNC School of Medicine, played a pivotal role in getting this therapy to the bedside, from assisting with clinical trials to the infusion of the first pediatric patient in North Carolina at UNC Children’s.

A new study in the lab of Bryan Roth, MD, PhD, at the UNC School of Medicine, helps us better understand how we perceive bitter taste on a chemical level. The findings may lead to the development of drugs that targeting taste receptors.

A woman with blonde hair and a white lab coat stands with hands in her pockets

A research study named Early Check has screened 1,000 newborns after birth in an effort to help identify rare conditions early, provide treatment, give parents educational information, and connect families with specialists throughout the state of North Carolina.

A multicenter, randomized, phase 3b trial, done in collaboration with a UNC School of Medicine researcher, found that once-daily oral semaglutide taken at higher doses of 25mg and 50mg improved regulation of blood sugar levels and weight loss compared to the standard 14 mg dose.

This nationwide clinical trial funded through the National Institutes of Health including participation from patients at the UNC Diabetes Center, led by John Buse, MD, PhD.

Laura Young, MD, PhD, associate professor of medicine, was UNC’s principal investigator for this six-month clinical trial that shows the use of continuous glucose monitoring (CGM) reduces serious levels of hypoglycemia compared with standard monitoring by daily use of blood glucose finger-stick test strips.

An international team of researchers co-led by UNC School of Medicine’s Karen Mohlke, PhD, conducted the largest-ever genome-wide study of people from across East Asia to uncover the genetic roots of type 2 diabetes.

Tag: Diabetes

UNC Study Shows Promise for Patients Who Struggle to Manage Type 2 Diabetes

Research Shows Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

Study Finds Oral Semaglutide Vastly Reduces Heart Attacks, Strokes

Diabetes Can Drive the Evolution of Antibiotic Resistance

Semaglutide Shows Promise in Reducing Cravings for Alcohol, Heavy Drinking

A New Therapy to Prevent or Delay Type 1 Diabetes Now Available at UNC Children’s Hospital

Researchers Discover How We Perceive Bitter Taste

A Newborn Genetic Screening Study Reaches New Milestone

Higher Doses of Oral Semaglutide Improves Blood Sugar Control and Weight Loss

Bionic Pancreas Improves Type 1 Diabetes Management Compared to Standard Insulin Delivery Methods

Continuous Glucose Monitoring Reduces Hypoglycemia in Older Adults with Type 1 Diabetes

First-in-Kind Study Reveals Genetic Markers of Type 2 Diabetes in East Asians